Explain vaccine derived polio virus and vaccine associated paralytic polio
Reading File
Finding Sources
Finding Sources
Searching PubMed
"vaccine-derived poliovirus" OR "VAPP" AND "oral polio vaccine"
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have all the information needed for a thorough, well-cited answer. Let me compile the response.
Vaccine-Derived Poliovirus (VDPV) and Vaccine-Associated Paralytic Polio (VAPP)
Both VDPV and VAPP are rare but important complications of the Oral Polio Vaccine (OPV / Sabin vaccine), which contains live attenuated poliovirus strains. They are distinct phenomena with different mechanisms, epidemiology, and public health implications.
Background: Why OPV Can Cause Disease
OPV works by delivering genetically attenuated (weakened) live poliovirus that replicates in the gut and induces both humoral (serum IgG) and mucosal (intestinal IgA) immunity. The attenuation comes from specific nucleotide mutations in the viral genome. However, because the vaccine virus is alive, it can mutate during replication. Under certain circumstances, these mutations can reverse the virus toward neurovirulence - the ability to cause paralytic disease.
Normal OPV replication in a recipient lasts 4-6 weeks, after which the attenuated vaccine virus is cleared. The problem arises when replication is prolonged - either in an immunocompromised host or through sustained community transmission in under-immunized populations.
1. Vaccine-Associated Paralytic Polio (VAPP)
Definition
VAPP is paralytic poliomyelitis that occurs directly as a result of OPV vaccination - either in the vaccine recipient or an unimmunized close contact who acquires the vaccine virus through fecal-oral spread.
Mechanism
- The Sabin vaccine strains carry attenuating mutations in the 5' untranslated region (5'UTR) and in viral capsid protein genes.
- During normal gut replication, these mutations can revert, partially restoring neurovirulence.
- In most people, the immune system clears the virus before neurovirulence becomes clinically significant.
- In the small minority where neuro-invasion occurs before clearance, VAPP results.
Epidemiology and Risk
- Incidence: approximately 1 case per 2.4 million doses of OPV distributed; the risk is highest after the first dose (~1 per 750,000 doses), as subsequent doses confer protective immunity - Red Book 2021, p. 938
- Global incidence: 4 cases per 1,000,000 birth cohort per year in countries using OPV - Park's Preventive & Social Medicine
- Before the US switched to all-IPV in 2000, there were approximately 6-8 cases per year of VAPP in the United States - Textbook of Family Medicine 9e
- Serotype distribution: Sabin type 3 accounts for ~60% of VAPP cases, followed by type 2 and type 1 - Park's Preventive & Social Medicine
- Immunocompromised individuals (especially primary B-lymphocyte/humoral immunodeficiencies like X-linked agammaglobulinemia) are at dramatically elevated risk - they cannot clear the vaccine virus effectively - Red Book 2021, p. 934
Who Gets VAPP?
| Group | Risk Level |
|---|---|
| First-dose OPV recipient | Highest (1 in 750,000 doses) |
| Subsequent dose recipient | Lower (existing immunity protective) |
| Unimmunized household contact | Significant |
| Immunocompromised individual | Greatly elevated |
Clinical Features
- Clinically indistinguishable from wild-type paralytic polio: asymmetric acute flaccid paralysis, areflexia, proximal muscle involvement more than distal, sensation intact, CSF showing viral meningitis pattern.
- Can cause residual paresis in approximately two thirds of affected patients.
- Bulbar involvement can impair respiration.
- Distinguished from wild-type polio only by laboratory analysis (genetic sequencing, rRT-PCR).
Prevention
- Switching to IPV (Salk vaccine) eliminates VAPP entirely, since IPV contains killed virus that cannot replicate or mutate.
- The US eliminated VAPP by switching to an all-IPV schedule in 2000.
- A sequential IPV-OPV schedule (IPV first, then OPV) reduces VAPP risk while still conferring intestinal mucosal immunity - Park's, p. 238
2. Vaccine-Derived Poliovirus (VDPV)
Definition
VDPV refers to poliovirus strains that originated from OPV but have undergone substantial genetic divergence from the parent Sabin strain - specifically >1% nucleotide divergence in the VP1 capsid region (equivalent to >10 nucleotide changes), indicating prolonged replication far beyond the normal 4-6 week window. VDPVs have biologically reverted to resemble wild-type poliovirus in terms of neurovirulence and transmissibility.
Distinction from VAPP
| Feature | VAPP | VDPV |
|---|---|---|
| Mechanism | Direct neurovirulence from short-term replication/reversion | Prolonged replication with extensive genetic divergence, restoring full wild-type-like properties |
| Genetic change | Minimal (early reversion) | >1% VP1 divergence from Sabin strain |
| Transmission | Limited (recipient or close contact) | Can sustain community-level transmission |
| Setting | Any OPV-using population | Low vaccination coverage populations or immunocompromised hosts |
Three Categories of VDPV
1. Circulating VDPV (cVDPV)
- Evidence of sustained person-to-person community transmission.
- Arises when OPV virus enters a population with low vaccination coverage - enough susceptible individuals to allow ongoing transmission and progressive genetic change.
- The mutated virus eventually acquires full neurovirulence and spreads like wild poliovirus.
- Notable outbreaks: Egypt (1983-1993), Nigeria (385 cases, 2005-2012), multiple African countries (223 cases in DRC in 2023 alone).
- In 2023, there were 526 cases of vaccine-derived polio from 24 countries; 96% from Africa - Harrison's 22E (2025)
- A case of cVDPV type 2 was documented in an unvaccinated adult in New York in 2022, genetically linked to local wastewater - Harrison's 22E, p. 1680
2. Immunodeficiency-associated VDPV (iVDPV)
- Occurs in patients with primary B-cell immunodeficiencies (e.g., agammaglobulinemia, common variable immunodeficiency) who cannot mount antibody responses to clear vaccine virus.
- OPV virus replicates persistently in the gut for months to years, accumulating mutations.
- These patients may excrete the evolving virus chronically.
- Found as incidentally shedding, often asymptomatic - e.g., 5 infants in Minnesota in 2005 found shedding VDPV with no symptoms - Harrison's 22E
- Serious risk: the iVDPV can eventually seed community transmission.
3. Ambiguous VDPV (aVDPV)
- Diverged virus detected in an individual or environment without clear evidence of either prolonged immunodeficiency or sustained community transmission.
- Source remains uncertain pending investigation.
Diagnosis
Diagnosis is made by real-time reverse transcription-PCR (rRT-PCR) targeting nucleotide substitutions that occur early in VDPV emergence, followed by sequencing to determine the degree of VP1 divergence. All poliovirus isolates are characterized through the Global Polio Laboratory Network (GPLN) - Park's, p. 238
Global Epidemiology
A striking reversal has occurred in the polio eradication era: more cases of paralytic polio are now caused by vaccine-related viruses (VAPP + cVDPV) than by wild polioviruses - Red Book 2021, p. 934. As of 2023:
- Wild-type polio: only 12 cases worldwide (only Pakistan and Afghanistan, only type 1)
- Vaccine-derived polio: 526 cases from 24 countries
The table below from Harrison's 22E (2025) illustrates this:
| Country | Wild-type Polio | Vaccine-Derived Polio |
|---|---|---|
| Pakistan | 6 | 0 |
| Afghanistan | 6 | 0 |
| DR Congo | 0 | 223 |
| Nigeria | 0 | 87 |
| Chad | 0 | 55 |
| Guinea | 0 | 47 |
The Type 2 Problem
- Wild-type poliovirus type 2 was eradicated in 1999 and declared eradicated in 2015.
- Following this, OPV was modified: trivalent OPV (tOPV) containing types 1, 2, and 3 was switched in April 2016 to bivalent OPV (bOPV) containing only types 1 and 3, removing the type 2 component.
- However, this left a growing cohort of children with no immunity to type 2, allowing cVDPV2 to emerge and spread in under-immunized pockets.
- From 2018 to 2020, 92% of vaccine-derived polio cases were type 2 - Harrison's 22E
- Response strategy: use of monovalent OPV type 2 (mOPV2) for outbreak response.
nOPV2: The Novel Solution
A novel oral polio vaccine type 2 (nOPV2) was genetically engineered with a more stable attenuating backbone that is impaired in reverting to neurovirulence. After ~700 million doses administered from 2021-2023, only 61 cases of paralysis were associated with nOPV2 - a dramatically lower rate of VDPV emergence compared to the original mOPV2 - Harrison's 22E, p. 1681. The 2024 review on nOPV2 (PMID 38668228) documents its role in global outbreak response.
Endgame Strategy
To eliminate both VAPP and VDPV, the WHO Polio Eradication Endgame Plan calls for:
- Introduce at least one dose of IPV into all routine immunization schedules (as risk mitigation).
- Global switch from tOPV to bOPV (completed April 2016).
- Eventually cease all OPV use worldwide - the only way to eliminate VDPV risk entirely.
- Maintain AFP (Acute Flaccid Paralysis) surveillance at certification standard: at least 1 non-polio AFP case per 100,000 under-15 children annually, with 80% having adequate stool specimens collected within 14 days of paralysis onset - Park's Preventive & Social Medicine
Summary Comparison
| Feature | VAPP | VDPV |
|---|---|---|
| Cause | OPV-derived virus with early reversion mutations | OPV-derived virus with >1% VP1 divergence |
| Replication time | 4-6 weeks (normal) | Prolonged (months to years) |
| Transmission | Recipient + 1 generation of contacts | Sustained community spread possible |
| Incidence | 1 per 2.4 million OPV doses | Rare but can cause outbreaks |
| At-risk groups | First-dose recipients; unimmunized contacts; immunocompromised | Under-immunized communities; immunocompromised (iVDPV) |
| Serotype burden | Mainly type 3 | Mainly type 2 (post-tOPV withdrawal) |
| Prevention | Switch to IPV | High vaccination coverage + IPV introduction + eventual OPV cessation |
| Clinical distinction from wild polio | None (lab only) | None (lab only) |
Sources:
- Park's Textbook of Preventive and Social Medicine, pp. 238, 5652-5696
- Harrison's Principles of Internal Medicine 22E (2025), pp. 1680-1681
- Red Book 2021 (AAP), pp. 934-938
- Systematic review on VAPP (PMID 38813942) - Suares et al., Expert Opin Drug Saf, 2024
- nOPV2 global outbreak response review (PMID 38668228) - Kurji et al., Pathogens, 2024
- VDPV type 2 outbreaks and nOPV candidates (PMID 41389444) - Aboshanab et al., Diagn Microbiol Infect Dis, 2026
Then does vdpv will cause paralysis in the recepient of vaccine?
This is a great conceptual question that gets to the heart of the VDPV vs VAPP distinction.
Short answer: Generally no - VDPV does not typically cause paralysis in the original vaccine recipient. Here is why:
The Timeline Problem
VDPV requires >1% nucleotide divergence in the VP1 region from the Sabin strain. This level of genetic change takes months to years of continuous replication to accumulate - far beyond the normal 4-6 week replication window in an immunocompetent OPV recipient.
By the time enough mutations have accumulated to create a true VDPV, the original vaccine recipient has already:
- Cleared the virus (their immune response eliminated it within 4-6 weeks)
- Developed protective immunity against the very virus they shed
So the original recipient is immune before the virus becomes dangerous enough to qualify as VDPV.
Who Then Gets Paralyzed by VDPV?
cVDPV (Circulating VDPV)
The vaccine recipient sheds the vaccine virus into the environment (fecal-oral route). In a community with low vaccination coverage, this virus passes from person to person - accumulating more mutations with each transmission cycle. After enough transmission cycles, it becomes a fully neurovirulent VDPV. It then paralyzes unvaccinated or under-vaccinated people in the community, just like wild poliovirus would.
The original vaccinated child is fine. The unimmunized neighbors get paralyzed.
iVDPV (Immunodeficiency-associated VDPV)
This is the key exception. A child with primary B-cell immunodeficiency (e.g., X-linked agammaglobulinemia) receives OPV and cannot clear it. The virus replicates persistently in their gut for months to years. Over this time it accumulates enough mutations to become iVDPV.
Here, the recipient themselves is at risk - both of:
- Chronic, persistent infection
- Potentially paralytic disease from the evolved virus
This is why OPV is absolutely contraindicated in immunocompromised individuals.
Recap: Who Gets Paralyzed and By What
| Scenario | Who gets paralyzed | Mechanism |
|---|---|---|
| VAPP | Vaccine recipient OR unimmunized close contact | Early reversion mutations during normal 4-6 week replication |
| cVDPV | Unvaccinated/under-vaccinated community members | Prolonged community transmission → full neurovirulence restored |
| iVDPV | The vaccine recipient themselves (immunocompromised) | Persistent replication in immunodeficient host → divergence within same person |
The Practical Bottom Line
- A healthy, immunocompetent OPV recipient almost never develops VDPV-related paralysis - they clear the virus too fast for VDPV to form.
- They can, however, get VAPP from early reversion - that is a different and faster process.
- The danger of VDPV to the vaccine recipient specifically applies to immunocompromised hosts (iVDPV).
- The community-level danger of cVDPV falls on unvaccinated people around the vaccinated child - which is the central irony of OPV: the vaccine that protects one child can, in low-coverage settings, eventually generate a virus that paralyzes another child who never received any vaccine at all.
This is a shared conversation. Sign in to Orris to start your own chat.